APA (7th ed.) Citation

Sunakawa, Y., Nakamura, M., Ishizaki, M., Kataoka, M., Satake, H., Kitazono, M., . . . Tsuji, A. (2019). PD-013 - RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). Annals of Oncology, 30, iv114. https://doi.org/10.1093/annonc/mdz156.012

Chicago Style (17th ed.) Citation

Sunakawa, Y., et al. "PD-013 - RAS Mutations in Circulating Tumor DNA (ctDNA) and Clinical Outcomes of Rechallenge Treatments with Anti-EGFR Antibodies in Patients with Metastatic Colorectal Cancer (mCRC)." Annals of Oncology 30 (2019): iv114. https://doi.org/10.1093/annonc/mdz156.012.

MLA (9th ed.) Citation

Sunakawa, Y., et al. "PD-013 - RAS Mutations in Circulating Tumor DNA (ctDNA) and Clinical Outcomes of Rechallenge Treatments with Anti-EGFR Antibodies in Patients with Metastatic Colorectal Cancer (mCRC)." Annals of Oncology, vol. 30, 2019, p. iv114, https://doi.org/10.1093/annonc/mdz156.012.